Technetium (99mTc) exametazime is a
radiopharmaceutical sold under the trade name Ceretec, and is used by
nuclear medicine physicians for the detection of altered regional cerebral perfusion in
stroke[1] and other cerebrovascular diseases. It can also be used for the labelling of
leukocytes to localise intra-
abdominal infections[2] and
inflammatory bowel disease.[3] Exametazime (the part without technetium) is sometimes referred to as hexamethylpropylene amine oxime or HMPAO, although correct chemical names are:[4]
^Moretti JL, Defer G, Cinotti L, Cesaro P, Degos JD, Vigneron N, et al. (1990). ""Luxury perfusion" with 99mTc-HMPAO and 123I-IMP SPECT imaging during the subacute phase of stroke". European Journal of Nuclear Medicine. 16 (1): 17–22.
doi:
10.1007/BF01566007.
PMID2307169.
S2CID11934803.